Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALDX NASDAQ:ALT NASDAQ:ENTX NASDAQ:LYEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$5.39-4.9%$5.42$1.14▼$7.20$322.84M0.83748,037 shs980,965 shsALTAltimmune$3.92-2.0%$3.72$2.90▼$11.16$345.97M0.072.99 million shs2.64 million shsENTXEntera Bio$2.65+5.6%$1.94$1.50▼$2.79$121.01M1.6891,098 shs524,206 shsLYELLyell Immunopharma$16.51-12.5%$12.84$7.65▼$30.00$317.17M-0.0767,636 shs61,736 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-4.94%-6.10%-2.71%+15.91%+3.26%ALTAltimmune-2.00%+0.26%+6.81%-5.31%-35.84%ENTXEntera Bio+5.58%+39.47%+42.47%+53.18%+50.57%LYELLyell Immunopharma-12.51%-6.99%+26.32%+69.33%-23.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$5.39-4.9%$5.42$1.14▼$7.20$322.84M0.83748,037 shs980,965 shsALTAltimmune$3.92-2.0%$3.72$2.90▼$11.16$345.97M0.072.99 million shs2.64 million shsENTXEntera Bio$2.65+5.6%$1.94$1.50▼$2.79$121.01M1.6891,098 shs524,206 shsLYELLyell Immunopharma$16.51-12.5%$12.84$7.65▼$30.00$317.17M-0.0767,636 shs61,736 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-4.94%-6.10%-2.71%+15.91%+3.26%ALTAltimmune-2.00%+0.26%+6.81%-5.31%-35.84%ENTXEntera Bio+5.58%+39.47%+42.47%+53.18%+50.57%LYELLyell Immunopharma-12.51%-6.99%+26.32%+69.33%-23.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics 2.25Hold$9.5076.25% UpsideALTAltimmune 2.38Hold$17.40343.88% UpsideENTXEntera Bio 2.50Moderate Buy$10.00277.36% UpsideLYELLyell Immunopharma 1.33Sell$15.00-9.15% DownsideCurrent Analyst Ratings BreakdownLatest ENTX, ALT, ALDX, and LYEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/8/2025ALDXAldeyra TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ALTAltimmuneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ENTXEntera BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LYELLyell ImmunopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ALDXAldeyra TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ALTAltimmuneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ENTXEntera BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LYELLyell ImmunopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$1.19 per shareN/AALTAltimmune$20K17,298.96N/AN/A$1.74 per share2.25ENTXEntera Bio$180K672.22N/AN/A$0.23 per share11.52LYELLyell Immunopharma$60K5,285.95N/AN/A$26.21 per share0.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$55.85M-$0.85N/AN/AN/AN/A-73.63%-50.61%11/6/2025 (Estimated)ALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)ENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)LYELLyell Immunopharma-$342.99M-$24.29N/AN/AN/A-552,328.31%-85.58%-68.85%11/6/2025 (Estimated)Latest ENTX, ALT, ALDX, and LYEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ALDXAldeyra Therapeutics-$0.17N/AN/AN/AN/AN/A11/6/2025Q3 2025LYELLyell Immunopharma-$2.81N/AN/AN/AN/AN/A8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/12/2025Q2 2025LYELLyell Immunopharma-$3.80-$2.89+$0.91-$2.89$0.00 million$0.01 million8/8/2025Q2 2025ENTXEntera Bio-$0.11-$0.06+$0.05-$0.06N/AN/A8/7/2025Q2 2025ALDXAldeyra Therapeutics-$0.21-$0.16+$0.05-$0.16$1.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A2.862.86ALTAltimmune0.0920.4420.44ENTXEntera BioN/A10.4710.47LYELLyell ImmunopharmaN/A7.657.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%ALTAltimmune78.05%ENTXEntera Bio14.11%LYELLyell Immunopharma66.05%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics9.60%ALTAltimmune4.40%ENTXEntera Bio10.38%LYELLyell Immunopharma22.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1059.90 million54.15 millionOptionableALTAltimmune5088.26 million84.37 millionOptionableENTXEntera Bio2045.66 million40.92 millionOptionableLYELLyell Immunopharma27019.21 million14.93 millionOptionableENTX, ALT, ALDX, and LYEL HeadlinesRecent News About These CompaniesLyell Immunopharma (NASDAQ:LYEL) Receives "Sell (D-)" Rating from Weiss RatingsOctober 10 at 7:50 AM | marketbeat.comClarius Group LLC Reduces Stake in Lyell Immunopharma, Inc. $LYELOctober 8 at 3:59 AM | marketbeat.comJohnson & Johnson Reduces Stock Holdings in Lyell Immunopharma, Inc. $LYELOctober 6, 2025 | marketbeat.comLyell Immunopharma (LYEL) Price Target Increased by 27.27% to 14.28September 30, 2025 | msn.comGoldman Sachs Group Inc. Has $193,000 Position in Lyell Immunopharma, Inc. $LYELSeptember 29, 2025 | marketbeat.comLyell Immunopharma initiated with a Buy at Lucid CapitalSeptember 26, 2025 | msn.comLyell Immunopharma initiated with a Buy at Lucid CapitalSeptember 26, 2025 | msn.comLUCID CAPITAL MARKETS Initiates Coverage of Lyell Immunopharma (LYEL) with Buy RecommendationSeptember 26, 2025 | msn.comLyell Immunopharma Advances CAR-T Candidate with Pivotal Head-to-Head TrialSeptember 19, 2025 | aktiencheck.deALyell Immunopharma CFO Resignation AnnouncedSeptember 16, 2025 | msn.comLyell Immunopharma Launches Phase III Trial of Dual-Targeted CAR T-Cell Therapy in Large B-Cell LymphomaSeptember 5, 2025 | precisionmedicineonline.comPLyell Immunopharma Positioned for Potential Breakthrough with Aggressive Clinical StrategySeptember 5, 2025 | aktiencheck.deALyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering ...September 3, 2025 | markets.businessinsider.comLyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering CommitteeSeptember 3, 2025 | globenewswire.comLyell Immunopharma Announces Participation in September Investor ConferencesSeptember 2, 2025 | globenewswire.comLyell Immunopharma Advances CAR T-Cell TherapiesAugust 14, 2025 | msn.comLyell Immunopharma trading resumesAugust 13, 2025 | msn.comLyell Immunopharma trading halted, volatility trading pauseAugust 13, 2025 | msn.comLyell Immunopharma, Inc: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025August 13, 2025 | finanznachrichten.deLyell Immunopharma files to sell 3.75M shares of common stock for holdersAugust 13, 2025 | msn.comLyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025August 12, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Bullish Case Remains Intact Despite Recent OfferingBy Ryan Hasson | September 24, 20253 Healthcare Stocks Using AI to Drive GrowthBy Chris Markoch | September 27, 2025Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut FrenzyBy Gabriel Osorio-Mazilli | September 21, 2025These 3 Crypto Stocks Could Get a Bump as Dollar Trust WeakensBy Nathan Reiff | September 27, 2025CVS Health Gains as Revenue Grows, Dividend Remains StrongBy Gabriel Osorio-Mazilli | September 25, 2025ENTX, ALT, ALDX, and LYEL Company DescriptionsAldeyra Therapeutics NASDAQ:ALDX$5.39 -0.28 (-4.94%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$5.35 -0.04 (-0.74%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Altimmune NASDAQ:ALT$3.92 -0.08 (-2.00%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$3.89 -0.03 (-0.77%) As of 10/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Entera Bio NASDAQ:ENTX$2.65 +0.14 (+5.58%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$2.68 +0.02 (+0.94%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Lyell Immunopharma NASDAQ:LYEL$16.51 -2.36 (-12.51%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$16.11 -0.40 (-2.45%) As of 10/10/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
